CMS Grants Fresenius Kabi COVID-19 Codes for Tyenne (tocilizumab-aazg)

The new HCPCS codes will help facilitate patient access to the COVID-19 treatment.

Apr. 9, 2026 at 5:48pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image revealing the intricate molecular structure of a COVID-19 treatment medication, conceptually illustrating the importance of improved access to this vital therapy.The new HCPCS codes for Fresenius Kabi's COVID-19 treatment Tyenne will help facilitate patient access to this critical medication.Lake Zurich Today

Fresenius Kabi, a leading provider of essential medicines and medical technologies, announced that the Centers for Medicare & Medicaid Services (CMS) has granted indication-specific HCPCS codes for Tyenne (tocilizumab-aazg), the company's COVID-19 treatment. The new codes will help facilitate patient access to the medication.

Why it matters

The availability of specific HCPCS codes for Tyenne is an important step in ensuring that patients with COVID-19 can access this critical treatment. HCPCS codes are used by Medicare and other payers to identify and reimburse healthcare services, so this designation will streamline the process for healthcare providers to prescribe and administer the drug.

The details

Fresenius Kabi's Tyenne (tocilizumab-aazg) is an IL-6 receptor antagonist approved for the treatment of COVID-19 in adult patients who are hospitalized and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The new HCPCS codes will allow for more efficient billing and reimbursement for the medication, which is expected to improve patient access.

  • The new HCPCS codes were granted by CMS on April 9, 2026.

The players

Fresenius Kabi

A leading provider of essential medicines and medical technologies, and a part of the Fresenius group.

Centers for Medicare & Medicaid Services (CMS)

The federal agency that administers the Medicare program and works in partnership with state governments to administer Medicaid.

Tyenne (tocilizumab-aazg)

Fresenius Kabi's COVID-19 treatment, an IL-6 receptor antagonist approved for use in adult patients hospitalized with COVID-19 who require supplemental oxygen, mechanical ventilation, or ECMO.

Got photos? Submit your photos here. ›

What’s next

The new HCPCS codes will allow healthcare providers to more easily prescribe and administer Tyenne to eligible COVID-19 patients, improving access to this critical treatment.

The takeaway

The CMS's decision to grant indication-specific HCPCS codes for Fresenius Kabi's Tyenne is an important development that will streamline the process for healthcare providers to offer this COVID-19 treatment to patients who need it.